IL15 and COVID-19: There are a number of Phase 1 (and some 2a) trials in the pipeline specifically for the implementation of allogenic NK cellular transfer, CAR-NK cells secreting an IL15 superagonist, and anakinra or rhIFNy adjunctives in COVID-19 and sepsis with hyperinflammation.